Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

Naoky Tsai,1 Lennox Jeffers,2 Lael Cragin,3 Sonja Sorensen,3 Wenqing Su,3 Lisa Rosenblatt,4 Hong Tang,4 Tony Hebden,4 Timothy Juday41John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; 2University of Miami School of Medicine, Miami, FL, USA; 3United BioSource Corporation, Bethe...

Full description

Bibliographic Details
Main Authors: Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T
Format: Article
Language:English
Published: Dove Medical Press 2012-08-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/cost-effectiveness-of-entecavir-versus-adefovir-for-the-treatment-of-c-a10786

Internet

http://www.dovepress.com/cost-effectiveness-of-entecavir-versus-adefovir-for-the-treatment-of-c-a10786

Similar Items